US › Healthcare

ENDRA Life Sciences Inc (NDRA)

US · Healthcare · Diagnostics & Research

$4.22+0.96%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-1.3M
Profit YoY
-26.5%
EPS
$-1.09
EPS estimate
$-1.23

EPS came in at -1.09 against a street estimate of -1.23 — a beat of 11.4%.

Key statistics

Market cap
$6.0M
Forward P/E
0.0
P/B
3.34
Book value
$1.44
EPS (TTM)
$-8.16
52-week high
$9.85
52-week low
$2.96
50-day MA
$5.02
200-day MA
$4.88
Beta
-0.07

Analyst view

Analysts rate ENDRA Life Sciences Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $25.00.

Shareholding

Insiders
8.73%
Institutions
9.66%

Largest institutional holders

FundStake
Altium Capital Management, LP4.09%
Geode Capital Management, LLC1.66%
Vanguard Fiduciary Trust Co0.80%
Morgan Stanley - Brokerage Accounts0.28%
Vanguard Capital Management, LLC0.22%
UBS Group AG0.01%
Northwestern Mutual Wealth Management Co0.00%
Caitong International Asset Management Co., Limited.0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ENDRA Life Sciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.